These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 33534617)

  • 1. A randomized, controlled, multicenter clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus moxifloxacin in adult patients with community-acquired pneumonia.
    Li Y; Zhu D; Peng Y; Tong Z; Ma Z; Xu J; Sun S; Tang H; Xiu Q; Liang Y; Wang X; Lv X; Dai Y; Zhu Y; Qu Y; Xu K; Huang Y; Wu S; Lai G; Li X; Han X; Yang Z; Sheng J; Liu Z; Li H; Chen Y; Zhu H; Zhang Y
    Curr Med Res Opin; 2021 Apr; 37(4):693-701. PubMed ID: 33534617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, active-controlled, multicentre clinical trial to evaluate the efficacy and safety of oral sitafloxacin versus levofloxacin in Chinese adults with acute uncomplicated or complicated urinary tract infection.
    Li Y; Yin Y; Peng X; Zheng H; Fu F; Liu Z; Wu X; Wu X; Zheng S; Chen N; He L; Ren L; Ni Z; Li D; Liang P; Lv X; Zhang Y
    Ann Med; 2021 Dec; 53(1):217-226. PubMed ID: 33331182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sitafloxacin- Versus Moxifloxacin-Based Sequential Treatment for Mycoplasma Genitalium Infections: Protocol for a Multicenter, Open-Label Randomized Controlled Trial.
    Ando N; Mizushima D; Shimizu Y; Uemura Y; Takano M; Mitobe M; Kobayashi K; Kubota H; Miyake H; Suzuki J; Sadamasu K; Nakamoto T; Aoki T; Watanabe K; Oka S; Gatanaga H
    JMIR Res Protoc; 2023 Nov; 12():e52565. PubMed ID: 37962941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicentre, randomised, double-blind, double-dummy, parallel-controlled, phase 3 clinical trial assessing the efficacy and safety of intravenous nemonoxacin malate vs. levofloxacin for community-acquired pneumonia in adult patients.
    Li Y; Zhu D; Sun S; Chang X; Cao Z; Yang Y; Fu X; Li X; Xu J; Zhu Y; Hui F; Xu X; Chen Z; Peng L; Ma Z; Mo B; Li C; Lv Y; Zhao L; Zhu G; He Y; Liu H; Chen J; Wang Y; Liang Y; Lu Y; Qin Z; Yang H; Zhang M; Wu S; Tong Z; Ye F; Xiao Z; Wang X; Qiu C; Kuang J; Huang H; Wang K; Ying K; Jin F; Lv X; Huang Y; Liu D; Wang W; Zhang Y
    Int J Antimicrob Agents; 2024 Aug; 64(2):107235. PubMed ID: 38851462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial.
    Alexander E; Goldberg L; Das AF; Moran GJ; Sandrock C; Gasink LB; Spera P; Sweeney C; Paukner S; Wicha WW; Gelone SP; Schranz J
    JAMA; 2019 Nov; 322(17):1661-1671. PubMed ID: 31560372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and survival findings after long-term follow-up of ZGJAK002: A phase 2 study comparing jaktinib at 100 mg twice daily (BID) and 200 mg once daily (QD) in patients with myelofibrosis.
    Zhang Y; Zhou H; Jiang Z; Wu D; Zhuang J; Li W; Jiang Q; Wang X; Huang J; Zhu H; Yang L; Du X; Li F; Xia R; Zhang F; Hu J; Li Y; Hu Y; Liu J; Jin C; Sun K; Zhou Z; Wu L; Yin H; Suo S; Yu W; Jin J
    Am J Hematol; 2024 Apr; 99(4):774-779. PubMed ID: 38343062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP).
    Horcajada JP; Salata RA; Álvarez-Sala R; Nitu FM; Lawrence L; Quintas M; Cheng CY; Cammarata S;
    Open Forum Infect Dis; 2020 Jan; 7(1):ofz514. PubMed ID: 31988972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of lascufloxacin for nursing- and healthcare-associated pneumonia: A single-arm, open-label clinical trial.
    Takazono T; Hosogaya N; Fukushima K; Morio R; Irifune S; Miyamura T; Harada Y; Nagayoshi Y; Kondo A; Mihara T; Fukuda Y; Sasaki E; Sawai T; Imamura Y; Morikawa T; Futsuki Y; Inoue Y; Fukushima K; Suyama N; Tanaka H; Hanaka T; Shimabukuro I; Hata R; Ota K; Morimoto S; Nakada N; Ito Y; Yoshida M; Takeda K; Ide S; Iwanaga N; Nemoto K; Funada M; Izumikawa K; Yatera K; Yanagihara K; Mukae H
    J Infect Chemother; 2024 Jul; 30(7):597-602. PubMed ID: 38190963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Sitafloxacin for
    Samra RS; Plummer EL; Vodstrcil LA; Aguirre I; Clarke EJ; Fairley CK; Chow EPF; Bradshaw CS
    Open Forum Infect Dis; 2023 Dec; 10(12):ofad590. PubMed ID: 38094665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moxifloxacin monotherapy for treatment of uncomplicated pelvic inflammatory disease: A systematic review and meta-analysis with trial sequential analysis of randomized controlled trials.
    Chen F; Dong Q; Hong W; Zhao J; Li Y
    Pharmacoepidemiol Drug Saf; 2023 Nov; 32(11):1189-1199. PubMed ID: 37655831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of efficacy and safety of lascufloxacin for nursing and healthcare associated pneumonia: single-arm, open-label clinical trial: A study protocol.
    Hosogaya N; Takazono T; Ota K; Kiya R; Shirai Y; Kawasaki R; Yano H; Morimoto S; Nakao R; Kanamaru Y; Yoshino Y; Ishikawa Y; Fukushima C; Yamamoto H; Izumikawa K; Yanagihara K; Mukae H
    Medicine (Baltimore); 2023 Feb; 102(8):e33092. PubMed ID: 36827005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug use evaluation of moxifloxacin (avelox) using a hand-held electronic device at a canadian teaching hospital.
    Samilski JA; Lau TT; Elbe DH; Aulakh AK; Lun EM
    P T; 2012 May; 37(5):291-9. PubMed ID: 22876087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxifloxacin is a safe and effective candidate agent for tuberculosis treatment: a meta-analysis of randomized controlled trials.
    Sun M; Fan J
    Ann Palliat Med; 2021 Feb; 10(2):2027-2035. PubMed ID: 33548992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Proton Pump Inhibitor Use and Risk of Asthma in Children.
    Wang YH; Wintzell V; Ludvigsson JF; Svanström H; Pasternak B
    JAMA Pediatr; 2021 Apr; 175(4):394-403. PubMed ID: 33555324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating
    Srivastava S; Cirrincione KN; Deshpande D; Gumbo T
    Front Pharmacol; 2020; 11():616294. PubMed ID: 33542690
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful Use of Rifamycin-Sparing Regimens for the Treatment of Active Tuberculosis in Lung Transplant Recipients.
    Almaghrabi RS; Nizami I; Alameer R; Alshehri N; Almohaizeie A; Alrajhi AA; Omrani AS
    Exp Clin Transplant; 2021 Apr; 19(4):359-366. PubMed ID: 33535940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection.
    Lodise TP; Mistry R; Young K; LaPensee K
    Clin Drug Investig; 2021 Mar; 41(3):269-275. PubMed ID: 33604769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications.
    Kaplan YC; Demir O
    Curr Neuropharmacol; 2021; 19(11):1805-1824. PubMed ID: 33573557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Otorhinolaryngological adverse effects of urological drugs.
    Maia NPD; Lopes KC; Ganança FF
    Int Braz J Urol; 2021; 47(4):747-752. PubMed ID: 33566468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mycoplasma hominis meningitis in an extremely preterm newborn: a case report.
    Ansari NS; Asztalos E; Rolnitsky A
    BMC Pediatr; 2021 Feb; 21(1):69. PubMed ID: 33557784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.